Danaher announced on September 6 that it will acquire US molecular diagnostics company Cepheid for $4 billion and the transaction will be completed in the fourth quarter of 2016. After the news was released, the Cepheid official website quickly verified the news. The transaction will be sold at a price of $53 per share, and the overall transaction volume will be as high as $4 billion! Compared to the Cepheid share price on Friday, the premium is as high as 54%! The Mofisher’s rumors of the acquisition of Illumina have not been dispersed some time ago. Danaher has confirmed such a heavy transaction, it seems that the giants (壕) buy and buy can not stop the rhythm! What kind of company is the $4 billion Cepheid? Cepheid's main business consists of clinical molecular diagnosis and POCT, targeting infectious diseases and tumor detection. The current products are as follows: Innovative jet embedded nylon technology maximizes the efficiency of sample collection from patients. Nylon adheres vertically and evenly to the surface of the swab tip, improving the efficiency of cell and liquid sample collection and release. Increased analytical sensitivity, no specimen residue, and accelerated specimen processing. Flocked Swab,Collect swabs from specimens with flocked tips,Medical sampling swab oral nylon swab flocking,Acts in the clinical diagnosis Jiangsu iiLO Biotechnology Co., Ltd. , https://www.sjiilobiotech.com.jpg)
.jpg)
.jpg)